Prosensa considers developing muscle disorder drug after new data

[riky]

Prosensa considers developing muscle disorder drug after new data

(Reuters) - Prosensa Holding NV said it would consider further developing its muscle disorder drug, which failed a key trial, after additional data showed the treatment could slow the progression of the disease, sending its shares up 50 percent. The news comes just days after Prosensa's partner, GlaxoSmithKline Plc, returned the rights to the drug, drisapersen, after it failed the late-stage study by GSK in September last year. Prosensa Chief Executive Hans Schikan said the results suggested that treating patients earlier and longer with the drug delayed the progression of the disease. Drisapersen was being developed to treat Duchenne muscular dystrophy, a rare muscle-wasting genetic disease affecting boys.

Source: You are not allowed to view links. Register or Login